OBJECTIVE: To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg.
METHODS: A total of 162 patients were included in this study. Of the patients, 108 were randomized to receive 4 mg doxazosin XL (group 1), and 54 were randomized to receive 8 mg (group 2) treatments. After 1 month of treatment, 31 patients in group 1 whose quality of life (QoL) score was unchanged or had deteriorated were switched to 8 mg doxazosin XL treatment (group 1b).
RESULTS: The mean age was 59.8 years. After 1 month of treatment, the mean alteration in the International Prostate Symptom Score was 3.9 and 5.2 (P = .028), for the maximum urinary flow rate (Qmax), it was 3.0 and 3.6 mL/s (P = .206), and for the QoL score it was 1.3 and 1.7 (P = .038) in groups 1 and 2, respectively. For group 1b, during the period in which the patients were receiving 4 and 8 mg doxazosin XL treatments; the International Prostate Symptom Score changes were 1.3 and 3.6 (P < .001), the Qmax changes were 1.6 and 3.2 mL/s (P < .019), and the QoL changes were 0.4 and 1.8 (P < .001) in groups 1 and 2, respectively.
CONCLUSION: With no changes in side effects, 8 mg doxazosin XL treatment is an efficient choice for patients who did not have an adequate response to 4 mg doxazosin XL treatment.
Written by:
Keten T, Aslan Y, Balci M, Tuncel A, Bilgin O, Dilmen C, Ozdemir U, Yahsi S, Guzel O, Atan A. Are you the author?
Third Department of Urology, Ministry of Health, Ankara Numune Research and Training Hospital, Ankara, Turkey; Department of Urology, Karatekin Hospital, Cankiri, Turkey; Department of Urology, Cankiri State Hospital, Cankiri, Turkey.
Reference: Urology. 2015 Jan;85(1):189-94.
doi: 10.1016/j.urology.2014.10.004
PubMed Abstract
PMID: 25530384